Pharmaceutics · 4 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It describes the static and dynamic ocular barriers that limit drug bioavailability and surveys various innovative strategies, including nanomedicines (liposomes, nanomicelles), sustained-release systems (ocular inserts, implants, hydrogels), and topical penetration enhancers.
It describes the static and dynamic ocular barriers that limit drug bioavailability and surveys various innovative strategies, including nanomedicines (liposomes, nanomicelles), sustained-release systems (ocular inserts, implants, hydrogels), and topical penetration enhancers.
